What We Do Best
Alveo Technologies is changing the world by applying cutting edge advances in sensing, microfluidics, and bioassays to create the next generation of disease and personal care diagnostic devices.
Our innovative products connect and empower consumers, healthcare professionals and treatment providers with the ability to know sooner, act faster, and make better-informed decisions. Advanced diagnostics clear the path to more personalized medicine and better outcomes.
In the waiting room, doctors’ office, at home or any low resource setting, our versatile product platform enables rapid, inexpensive, and dependable screening.
Who We Are
We are scientists, innovators, data-geeks, and passionate entrepreneurs. We believe that every problem has a clear solution — when you apply the right knowledge and passion. We know that protecting the health of an interconnected global society has never been more crucial.
We’re up to the challenge. We are proud to be Alveo.
Meet the team that is changing the world of diagnostics.
RON CHIARELLO, PhD
Ron is the Chief Executive Officer, a Founder, and a member of the Board of Directors of Alveo Technologies. He is an entrepreneur and technology visionary with over 25 years of experience in the development and commercialization of solid state physics and semiconductor instrumentation for Semiconductor and Life Sciences applications. Alveo is Ron’s third start-up; his first two companies were both acquired with investors realizing a 20x return on investment.
Ron earned a B.S. in Physics from the University of California at Santa Barbara and received his Doctorate in Physics from Northeastern University. Prior to his entrepreneurial career Ron spent more than a decade as a physicist and research program director at the University of Chicago and Stanford University. He has authored more than 50 scientific publications and patents, is an NSF Fellow, and has received awards for excellence from the Department of Energy, Argonne National Laboratory, the Chevron Clean Technology Open, and International Sematech.
MIKE AICHER, MBA
Mike is the President and a Founder of Alveo Technologies. Prior to Alveo, Mike co-founded and served as National Genetics Institute’s (NGI) CEO from 1991 to 2012. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions. He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He has also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.
LAWRENCE BLATT, PhD, MBA
Larry is a Founder and is Chairman of the Board of Directors of Alveo Technologies as well as responsible for co-leading the Infectious Diseases & Vaccines (IDV) Therapeutic Area at Janssen Research & Development. Prior to joining the Johnson & Johnson Family of Companies, Larry founded and was President and Chief Executive Officer of Alios BioPharma, Inc., the clinical stage biopharmaceutical company focused on developing therapies for viral diseases that was acquired by Johnson & Johnson in 2014. He was named as key inventor on several Alios patents and won the 2012 Ernst & Young Entrepreneur of the Year Award for Life Sciences.
Larry spent 30 years in pharmaceutical R&D with a specific focus on the biology of the immune system, antiviral therapies and relevant therapeutic interventions. Before forming Alios, he was Chief Scientific Officer of InterMune, Inc. where he led the discovery and development of an HCV protease inhibitor partnered with Roche. From 1998 to 2002, Larry was Vice President of Research at SIRNA. From 1996 to 1998, he served as Vice President, Product Development at National.
Larry earned his B.S. in Microbiology from Indiana University, a Masters in Business Administration at the California State University, Northridge, and a Doctorate in Public Health Administration at the University of La Verne, California.
SUMITA PENNATHUR, PhD
Sumita is a Founder and member of the Scientific Advisory Board of Alveo Technologies. She is a Professor of Mechanical Engineering at the University of California at Santa Barbara. Sumita’s major contributions to nanofluidics and interfacial science have been disseminated in the form of over 60 archived journal publications, books or conference papers, multiple patent applications, and over 50 invited presentations. Notable awards include the DARPA young faculty award (2008), the UC Regents Junior Faculty Fellowship (2009), the PECASE (presidential early career award in science and engineering) award (2010), and the Santa Barbara Chamber of Commerce Innovator of the Quarter Award (2012). Sumita received her B.S. and M.S. in Aerospace and Aeronautical Engineering from M.I.T. (2000 and 2001 respectively), and Ph.D. in Mechanical Engineering from Stanford University (2006).
ISAAC BLECH, BA
Isaac is the Vice Chairman of the Alveo Board of Directors. He is a biotechnology entrepreneur and investor who, during the past 30+ years, has founded and served on the boards of a number of companies which have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and brain cancer. The companies he founded include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation and Genetics Systems Corporation. Isaac is a major stockholder and Vice Chairman of Cerecor, Inc., and major stockholder and Vice Chairman of Edge Therapeutics. He is also a major stockholder and Vice Chairman of The SpendSmart Payments Company as well as a major stockholder and Vice Chairman of root9B Technologies, Inc. (formerly Premier Alliance Group) (OTC: RTNB). Isaac is Vice Chairman of RestorGenex, Vice Chairman of Centrexion Corporation and a director of Medgenics, Inc. (NYSE: MDGN) and ContraFect Corporation (NASDAQ: CFRX). Isaac earned a B.A. degree from Baruch College in 1975.
ROBIN STEELE, JD, LL M
Robin is a member of the Alveo Board of Directors and has practiced corporate and tax law for 30 years, primarily in the biotechnology and pharmaceutical industries. She has extensive experience in financings, collaborations and M&A. Most recently Robin served 10 years as Senior Vice President and General Counsel to InterMune, Inc., a publicly traded (NASDAQ) biopharmaceutical company that was acquired by Roche in late 2014. Robin previously served 8 years as Vice President of Legal Affairs for Elan Pharmaceuticals, a publicly traded (NYSE) global pharmaceutical company headquartered in Dublin, Ireland. Robin received a bachelor’s degree in biology from the University of Colorado, a J.D. degree from the University of California, Hastings College of the Law, and a LL.M. in Taxation from New York University School of Law.
JOHNSON CHIANG, PhD
Previous to Alveo, Johnson was the Head of Systems Integration & Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific where he led systems design, integration, verification and validation for qPCR and Next-Gen Sequencing platforms.
Johnson has led a number of molecular diagnostic product development projects from concept to commercialization at Applied MEMS, Applied Biosystems Inc., and Cepheid; designed and developed several successful microfluidics products; filed several patents; and published numerous biotechnology papers. He has extensive experience in instrument development as well as design control for 510k and PMA applications.
Brenna is the Operations Director at Alveo Technologies. She balances diverse responsibilities for the company, including IP, HR, Recruiting, Quality, Regulatory, Facilities, Event Coordination, Contracts, and Communications. Prior to Alveo, Brenna held a variety of technical and leadership roles at Guidant Corporation/Abbott Vascular from 2004 to 2014, including: Group Lead of the design team for R&D implant projects, Principal/Staff Engineer focused on scaffold design and transfer to manufacturing for the first drug-eluting bioresorbable vascular scaffold to treat coronary artery disease, and Co-Chair of the Abbott Vascular Technology Exposition (2011-2012). Brenna has successfully supported and led development of multiple medical device products from early concept stage through design control, verification and validation, and regulatory submission. She holds 10+ patents and received the Abbott Vascular R&D Excellence Award in 2006, 2009, and 2010. Brenna earned her B.S. and M.S. degrees from Stanford University in Mechanical Engineering.
Kyle is the Engineering Director at Alveo Technologies, guiding products from early stage R&D to manufacturing. At Alveo, Kyle has held roles of increasing responsibility including New Product Development Engineer and Engineering Manager. Prior to his time with Alveo, Kyle worked at Entegris Jetalon as a New Product Development Engineer, serving as the team lead and taking multiple semiconductor sensor products from concept to market. Kyle received his BS degree from Arizona State University in Earth and Space Exploration.
Shad is the Senior Hardware Engineer / Technology Architect at Alveo Technologies. Shad conceptualizes technical solutions to bring visionary ideas to the benchtop for testing. His contributions range from algorithm development to PCB design and bring-up to new intellectual property generation. Prior to Alveo, Shad worked at Entegris Jetalon as a Research Engineer, guiding the early stage development of multiple products. Shad has a Bachelor’s degree in Mathematics from the University of California, Davis.
RIXUN FANG, PhD
Rixun brings over 20 years of experience in IVD development to his role as Alveo’s Director of Assay Development. He has successfully led many projects from inception through development and implementation at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific, following GMP/QSR/ISO compliances and the PCP process. He has worked through IVD product 510k and PMA submissions with FDA, initiated and led collaborative projects with many internationally well-known institutions, holds 6 patents, and has authored multiple publications.
Scientific Advisory Board Members
SUMITA PENNATHUR, PHD – Founder
Professor of Mechanical Engineering, UCSB, Director of Pennathur Laboratory for nanotechnology for bio sensing
PAUL BILLINGS, MD PHD
Chief Medical Officer, Life Technologies, Inc. acquired by Thermo Fisher (2014)
JAY G WOHLGEMUTH, MD
Chief Medical Officer, Quest Diagnostics
MARCIA EISENBERG PHD
Chief Scientific Officer, LabCorp
ROGER HAWLEY, BS
CEO/Co–Founder of Zogenix (ZGNX)
CHARLES MOSHER, MBA
President and CEO of HemaStrat LLC
MYRON TONG, MD PhD
World–leading Hepatologist, practicing physician at UCLA Medical Center
KEVIN PLAXCO, PhD
Professor of Biomolecular Science and Mechanical Engineering, and the Associate Director of The Center for Bioengineering at UCSB